Federal grants to Novomedix LLC
Novomedix LLC in San Diego, California received $3.5 million in federal grants from fiscal 2021 to 2025, across 5 awards. Its largest program was Cardiovascular Diseases Research, with $3.2 million. In fiscal 2025 it was awarded $314,362.
From USAspending.gov award records, updated November 7, 2026.
- Grants, FY 2021 to 2025$3.5 million
- Awards5
- Awarded in FY 2025$314,362
- Largest award$2.0 million
By year
| Fiscal year | Awards | Amount |
|---|---|---|
| FY 2021 | 1 | $375,000 |
| FY 2022 | 1 | $1.1 million |
| FY 2023 | 1 | $930,592 |
| FY 2024 | 2 | $806,872 |
| FY 2025 | 1 | $314,362 |
Programs that fund Novomedix LLC
| Program | Awards | Amount |
|---|---|---|
| Cardiovascular Diseases Research | 4 | $3.2 million |
| Arthritis, Musculoskeletal and Skin Diseases Research | 1 | $314,362 |
Awarding agencies
| Agency | Awards | Amount |
|---|---|---|
| Department of Health and Human Services | 5 | $3.5 million |
Largest awards
| Award | Program | First action | Amount |
|---|---|---|---|
| Novel small molecules for protection against doxorubicin cardiotoxicity in tnbc - abstract the overall goal of this program is the development and commercialization of a novel, safe, and effective, therapy that synergizes with anthracyclines, such as doxorubicin (dox, adriamycin), to maintain or imp | Cardiovascular Diseases Research | May 4, 2022 | $2.0 million |
| Definitive (GLP) toxicity and toxicology studies for a novel small molecule for protection against cardiotoxicity in triple negative breast cancer - abstract the overall goal of this program is the development and commercialization of a novel, safe, and effective, therapy that synergizes with anthra | Cardiovascular Diseases Research | September 10, 2024 | $500,000 |
| Novel therapy for protection against diabetes and its complications in ischemic heart disease - abstract the overall goal of this program is the development and commercialization of a novel, safe, and effective therapy for diabetic cardiovascular disease (DCVD). The worldwide prevalence of diabetes | Cardiovascular Diseases Research | August 31, 2021 | $375,000 |
| Arthrofibrosis control using small molecule inhibitors of INTERLEUKIN-11 - abstract this program aims to develop and commercialize a novel, safe, and effective therapy for arthrofibrosis (AF) to reduce and potentially reverse fibrous tissue deposition, reduce pain and stiffness, and improve the rang | Arthritis, Musculoskeletal and Skin Diseases Research | September 22, 2025 | $314,362 |
| Novel oral small molecules for progressive pulmonary fibrosis - abstract the overall goal of this program is the development and commercialization of a novel, safer, and more effective, therapy for the treatment of idiopathic pulmonary fibrosis (IPF). Ipf is a progressive and generally fatal disease | Cardiovascular Diseases Research | September 18, 2024 | $306,872 |
Questions people ask
How much federal grant money does Novomedix LLC get?
$3.5 million in 5 grant awards from fiscal 2021 to 2025, as obligations reported to USAspending.gov.
Which agency gives Novomedix LLC the most?
The Department of Health and Human Services, with $3.5 million in 5 awards.
What is Novomedix LLC's largest federal grant?
$2.0 million under Cardiovascular Diseases Research, with its first action in the period on May 4, 2022. That counts only the money obligated in fiscal 2021 to 2025.
Which federal programs fund Novomedix LLC?
Its largest are Cardiovascular Diseases Research and Arthritis, Musculoskeletal and Skin Diseases Research.
Other grant recipients in San Diego
- San Diego Association of Governments
- Metropolitan Transit System
- General Atomics
- Neighborhood House Association
- San Diego County Regional Airport Authority
- San Diego State University Foundation
- San Diego Unified School District
- Family Health Centers of San Diego Inc
Largest federal grant recipients in California · Federal grants in California